CERS Cerus Corporation
2.290USD-2.14%Mkt Cap: 461.49M $P/E: —1d ago
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a propriet…
Industry Peers
Medical Devices$171.97BUSDP/E 31.8
$109.38BUSDP/E 21.0
$105.64BUSDP/E 28.5
$60.26BUSDP/E 16.8
$49.39BUSDP/E 51.1
$46.91BUSDP/E 19.6
$31.81BUSDP/E 33.5
$29.42BUSDP/E 14.9
$22.87BUSDP/E 18.7
$23.55BUSDP/E 18.0
$20.44BUSDP/E 25.6
$17.11BUSDP/E 28.0
$16.88BUSDP/E 21.5
$12.46BUSDP/E 77.7
$11.25BUSDP/E 18.3
$9.87BUSDP/E 28.0
$10.16BUSD
$9.92BUSD
$9.90BUSDP/E 18.9
$9.85BUSDP/E 46.6
| Headline | Source | Time |
|---|---|---|
Older | ||
 Cerus Q2 Earnings Call Highlights Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas. Product revenue totaled $57.4 million for the quarter ended June | ||